Proactive Investors - Run By Investors For Investors

Clinigen expecting good growth from all three operations in second half

Clinigen Group PLC (LON:CLIN) chief executive Shaun Chilton discusses the group's half year trading update with Proactive's Andrew Scott.

Chilton says they're well positioned for another year of growth with trading at the halfway stage in line with expectations.

Revenues were up 28% year-on-year, although the figure was distorted by what are called ‘pass through costs’ associated with the unlicensed medicines it accesses on behalf of patients in need.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full CLIN profile View Profile

Clinigen Group PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use